Dasatinib + Quercetin (Senolytic Stack) vs Retatrutide

Mechanism

Dasatinib is a multi-kinase inhibitor (targeting SRC, ABL, c-KIT, PDGFR, and ephrin receptors) originally developed for chronic myeloid leukemia. Quercetin is a natural flavonoid that inhibits PI3K, serpine/PAI-2, BCL-xL, and other anti-apoptotic pathways. Together, they constitute a senolytic combination that selectively induces apoptosis in senescent cells by disabling the senescent cell anti-apoptotic pathways (SCAPs) that allow damaged, non-dividing cells to resist programmed cell death. Senescent cells accumulate with aging and secrete the SASP (senescence-associated secretory phenotype) — inflammatory cytokines, matrix metalloproteinases, and growth factors that drive tissue dysfunction. By clearing senescent cells, D+Q reduces SASP-driven chronic inflammation.

Standard Dosing

Research indicates Dasatinib 100 mg + Quercetin 1000-1250 mg orally for 2 consecutive days, repeated every 2-4 weeks (intermittent 'hit-and-run' dosing).

Timing

Take both compounds together on dosing days, with or without food. The 'hit-and-run' approach exploits the fact that senolytic effect occurs rapidly but senescent cells take weeks to re-accumulate. Quercetin bioavailability is improved by fat co-ingestion.

Cycle Duration

Ongoing intermittent cycles. Long-term safety data in healthy populations is limited. Typically used in periodic courses (e.g., 2 days per month for 3-6 months, then reassess).

Side Effects

• GI discomfort, nausea, diarrhea (both compounds)
• Fluid retention and peripheral edema (dasatinib)
• Headache
• Thrombocytopenia and neutropenia (dasatinib — typically mild at senolytic doses)
• Pleural effusion (rare at intermittent dosing; more common with chronic oncology dosing)
• Skin rash

Contraindications

• Active bleeding disorders or thrombocytopenia
• Severe hepatic impairment
• Pulmonary arterial hypertension
• QT prolongation risk or concurrent QT-prolonging drugs
• Pregnancy and breastfeeding
• Active infections (temporary immunosuppression)

Best Stacking Partners

Mechanism

Triple incretin agonist (GIP/GLP-1/glucagon receptor). Combines appetite suppression and insulin sensitization of GLP-1 with the thermogenic and lipolytic effects of glucagon receptor activation. Produced the greatest weight loss of any anti-obesity agent in Phase 2 trials (~24% at 48 weeks).

Contraindications

• Not FDA-approved
• Presumed similar to GLP-1 class — MTC, pancreatitis, severe GI disease